Movers and SHAKERS
PDS Biotechnology Corp (PDSB)
Versamune-based COVID-19 Vaccine Consortium Received Brazilian Government Grant
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Supporting funding of $US60 million for the coronavirus program. PDS Biotech, Farmacore, and Blanver consortium received a commitment from the Secretary for Research and Scientific Training of the Ministry of Science, Technology, and Innovation of Brazil (MCTI). The funding of approximately US$60 million will be used to support the clinical development and commercialization of a novel, Versamune-based, second-generation COVID-19 vaccine in Brazil.
Near-term value-generating catalysts. We believe the company has multiple inflection points to generate value including a) PDS0101 preliminary efficacy data anticipated in Q2 2021 and b) PDS0203 safety and immunogenicity data projected in Q4 2021/Q1 2022 ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.